Search

Clinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar

Therapeutic area :

Stringer F., Jongh J.d, Ploeger B., Scott G., Urquart R. and Danhof M., Clinical impact of genetic polymorphisms observed in the pharmacokinetics of the novel PPAR agonist, Sipoglitazar. Noordwijkerhout.(2010)

Our expertise

General modelling Anti-infectives and immunology Methods Blood disorders Oncology Pain Safety pharmacology Diabetes CNS Gastrointestinal Diseases Anesthesiology Endocrinology/Sexual health Lung Diseases Cardiovascular Peripheral Nervous System Biologicals Paediatrics